Kilitch Drugs (India) Limited (KILITCH) Price & Analysis

Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for export. Their extensive portfolio includes a broad spectrum of parenteral and nasal formulations, addressing various therapeutic categories such as gastroenterology, anti-inflammatory conditions, epilepsy, malaria, and infections, among others. These are available in diverse formats like ampoules, vials, and dry powder injectables, and feature specialized offerings like iron supplements, metered nasal drops, and proprietary brands such as Klavmox and Onecef. The company also manufactures a variety of oral medications, including tablets, capsules, dry syrups, gripe water, and oral liquids and powders, targeting areas such as antibiotics, anti-diabetics, and cardiovascular health. Beyond traditional pharmaceuticals, Kilitch offers effervescent tablets and powders, exemplified by products like ROIPAR, DUREGRA, ROIVIT, and PH-7, as well as nutritional products such as CELTINE. Their innovative solutions include C-Seal, a topical skin adhesive designed for closing wounds without sutures. Furthermore, their product range extends to cosmetics and herbal remedies, encompassing various oils, lotions, liquids, creams, and pastes for skin, personal, and hair care, alongside herbal supplements for conditions like sore throat, prostate issues, diabetes, obesity, and libido enhancement.